title: Immunosuppression by co-stimulatory molecules: inhibition of CD2-CD48/CD58 interaction by peptides from CD2 to suppress progression of collagen-induced arthritis in mice.
abstract: Targeting co-stimulatory molecules to modulate the immune response has been shown to have useful therapeutic effects for autoimmune diseases. Among the co-stimulatory molecules, CD2 and CD58 are very important in the early stages of generation of an immune response. Our goal was to utilize CD2-derived peptides to modulate protein-protein interactions between CD2 and CD58, thereby modulating the immune response. Several peptides were designed based on the structure of the CD58-binding domain of CD2 protein. Among the CD2-derived peptides, peptide 6 from the F and C β-strand region of CD2 protein exhibited inhibition of cell-cell adhesion in the nanomolar concentration range. Peptide 6 was evaluated for its ability to bind to CD58 in Caco-2 cells and to CD48 in T cells from rodents. A molecular model was proposed for binding a peptide to CD58 and CD48 using docking studies. Furthermore, in vivo studies were carried out to evaluate the therapeutic ability of the peptide to modulate the immune response in the collagen-induced arthritis (CIA) mouse model. In vivo studies indicated that peptide 6 was able to suppress the progression of CIA. Evaluation of the antigenicity of peptides in CIA and transgenic animal models indicated that this peptide is not immunogenic.
authors.affiliation: Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana at Monroe, Monroe, LA 71201, USA.
authors.forename: Ameya
authors.initials: A
authors.lastname: Gokhale
authors.forename: Shanthi
authors.initials: S
authors.lastname: Kanthala
authors.forename: John
authors.initials: J
authors.lastname: Latendresse
authors.forename: Veena
authors.initials: V
authors.lastname: Taneja
authors.forename: Seetharama
authors.initials: S
authors.lastname: Satyanarayanajois
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000906:Antibodies / Q000737:chemistry / Q000276:immunology; D015703:Antigens, CD / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D001169:Arthritis, Experimental / Q000188:drug therapy / Q000473:pathology; D001665:Binding Sites; D018801:CD2 Antigens / Q000737:chemistry / Q000378:metabolism*; D000071178:CD48 Antigen; D018968:CD58 Antigens / Q000737:chemistry / Q000276:immunology / Q000378:metabolism*; D018938:Caco-2 Cells; D002448:Cell Adhesion / Q000187:drug effects; D005456:Fluorescent Dyes; D006801:Humans; D007165:Immunosuppression Therapy; D019169:Jurkat Cells; D051379:Mice; D008811:Mice, Inbred DBA; D008822:Mice, Transgenic; D062105:Molecular Docking Simulation; D010456:Peptides, Cyclic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011485:Protein Binding; D017433:Protein Structure, Secondary; D017434:Protein Structure, Tertiary
chemical_list: D000906:Antibodies; D015703:Antigens, CD; D018801:CD2 Antigens; D000071178:CD48 Antigen; C000604065:CD48 protein, human; D018968:CD58 Antigens; C000604066:Cd48 protein, mouse; D005456:Fluorescent Dyes; D010456:Peptides, Cyclic